Petrelintide
Human amylin analogue
Petrelintide is an investigational peptide that acts on the amylin pathway and is being studied for weight management. ZUPREME 1, a randomized phase 2 trial in adults with overweight or obesity, reported greater weight reduction with petrelintide than with placebo at 42 weeks. A separately registered phase 3 trial studies people with overweight or obesity and type 2 diabetes. Registration describes the research plan.
Evidence Level: Moderate Evidence
Some human data, strong animal studies, plausible mechanism
Regulatory Status: Investigational. No FDA-approved product for weight management was identified in this review.
How It Works
Potential Benefits
- ZUPREME 1, a randomized phase 2 trial in adults with overweight or obesity, reported greater weight reduction with petrelintide than with placebo at 42 weeks.
Risks & Considerations
- A trial result applies to the preparation and people studied. Long-term benefits and harms still need study. Results from separate trials cannot establish which medicine works better.
Key Research
Petrelintide for the treatment of obesity (ZUPREME 1)
The Lancet, 2026
ZUPREME 1, a randomized phase 2 trial in adults with overweight or obesity, reported greater weight reduction with petrelintide than with placebo at 42 weeks.
View StudySources and regulatory records
Frequently Asked Questions
Is petrelintide FDA-approved for weight management?
No FDA-approved product for this use was identified. The evidence on this page describes study preparations.
How does this fit alongside other weight medicines?
It acts on the amylin pathway. The category comparison links to the studied or approved use for each medicine and explains what readers can compare.
Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated November 2026.
See a problem or outdated information? Tell us.